Showing 1 to 1 of 1 results
theguardian.com
🌐 75% Global Worthiness
Moderna Vaccine Deal Bypasses Australian Assessment
Australia's $2 billion deal with Moderna for onshore mRNA vaccine manufacturing bypasses the Pharmaceutical Benefits Advisory Committee (PBAC) assessment, raising concerns about transparency and cost-effectiveness, prompting an investigation and criticism from health experts and competitors.
Moderna Vaccine Deal Bypasses Australian Assessment
Australia's $2 billion deal with Moderna for onshore mRNA vaccine manufacturing bypasses the Pharmaceutical Benefits Advisory Committee (PBAC) assessment, raising concerns about transparency and cost-effectiveness, prompting an investigation and criticism from health experts and competitors.
Progress
52% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results